An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioma; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms The Strata Trial
- Sponsors Strata Oncology
- 04 Jun 2024 Results assessing antibody drug conjugates -Treatment Response Scores in two cohorts of patients treated with approved ADCs, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results assessing immunotherapy response score for predicting pembrolizumab clinical benefit in patients with advanced solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 19 Apr 2023 Results (n=176) assessing an integrative Immunotherapy Response Score performance for predicting pembrolizumab mono benefit in a second, independent validation cohort, presented at the 114th Annual Meeting of the American Association for Cancer Research.